Sunday, June 14, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 159 of 1,261
  1. US 11806369

    Exosomes and miRNA to treat glaucoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  2. US 11806318

    Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  3. US 11807636

    IRAK degraders and uses thereof

    Kymera Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  4. US 11806360

    Compositions and methods for treating transthyretin (TTR) mediated amyloidosis

    Alnylam Pharmaceuticals, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  5. US 11806406

    Virus-like particle conjugates for diagnosis and treatment of tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  6. US 11807629

    Polymorphs of Selinexor

    Karyopharm Therapeutics Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  7. US 11806367

    Methods of treating lysosomal disorders

    The Regents of the University of California · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  8. US 11807649

    Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2

    EnLiven Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  9. US 11806429

    Film formulations containing dexmedetomidine and methods of producing them

    BioXcel Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  10. US 11806408

    Methods and compositions for treating cone-rod retinal dystrophy

    Editas Medicine, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  11. US 11807605

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  12. US 11806400

    Injectable ibuprofen formulation

    Cumberland Pharmaceuticals Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  13. US 11806389

    Compositions and methods for treating central nervous system injury

    The United States Government as Represented by The Department of Veteran Affairs · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  14. US 11806385

    Biomarkers for monitoring immune transformation

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  15. US 11806353

    Methods of treating liver disorders or lipid disorders with a THR-beta agonist

    Madrigal Pharmaceuticals, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  16. US 11807682

    M971 chimeric antigen receptors

    The United States of America, as represented by the Secretary, Department of Heath and Human Services · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  17. US 11806337

    Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  18. US 11807646

    4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19)

    ALMAC DISCOVERY LIMITED · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  19. US 11806432

    Compositions, methods and uses for thermally stable multi-targeted antigens

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  20. US 11806334

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  21. US 11807853

    Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  22. US 11806354

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  23. US 11806336

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  24. US 11807674

    Hepcidin analogues and uses thereof

    Protagonist Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.